OS-01 (Peptide 14): Side Effects

Important Safety Notice#

OS-01 (Peptide 14) is a cosmetic ingredient, not an FDA-approved drug. The safety data below comes from a limited number of industry-sponsored clinical trials with short duration (12 weeks maximum) and small sample sizes (22-60 participants). Long-term safety data is not available. No independent safety assessments have been conducted.

Reported Side Effects#

Clinical Trial Safety Data#

Across three published clinical trials (total approximately 104 participants exposed to OS-01), the safety profile of topical OS-01 formulations appears favorable:

• No serious adverse events were reported in any published clinical trial
• No significant cytotoxicity was observed in preclinical cell models, even at concentrations above those used therapeutically
• Skin tolerability was acceptable across face, body, and periorbital applications

The preclinical study (PMID: 37217561) specifically noted that Peptide 14 reduced senescence "without inducing significant toxicity" in cell culture models.

Limitations of Safety Data#

The current safety evidence is limited by:

• Maximum exposure duration of 12 weeks
• Total of approximately 104 participants across all trials
• Only female participants in clinical studies
• Industry-sponsored research without independent safety monitoring
• No formal pharmacovigilance or adverse event reporting system
• Topical application only -- systemic safety not formally assessed

Contraindications#

No formal contraindications have been established for OS-01, as it is a cosmetic ingredient without regulatory drug review. General precautions include:

• Avoid use on open wounds or severely damaged skin
• Discontinue if irritation or allergic reaction occurs
• Individuals with known allergies to formulation components should review ingredient lists

Drug Interactions#

No drug interaction studies have been conducted for OS-01 topical formulations. Given the topical route of administration, systemic drug interactions are considered unlikely, though the observation of systemic cytokine changes in the 2025 RCT (decreased IL-8) suggests some level of systemic absorption or systemic signaling that has not been fully characterized.

Individuals using prescription topical medications (retinoids, corticosteroids) should consult their dermatologist before combining with OS-01 products, as potential interactions have not been studied.